tonixpharma.com - רווח החברה לפני מסים, ריבית ופחת TNXP

Tonix Pharmaceuticals (TNXP) minimizes risks through a diversified development pipeline in the fields of infectious diseases and neuropathic pain. Current EBITDA levels clearly demonstrate the volatility of operating cash flows, where the current value is 0.00. Profit growth is based on preparations to launch fibromyalgia treatments to market. Massive demand potential in the US promises the company a rapid expansion of its customer base.

This indicator measures real cash flow from core operations, allowing for an assessment of the business's ability to generate cash excluding financial and tax factors. The EBITDA_Co valuation analysis reveals the resilience of Tonix Pharmaceuticals (TNXP) operational processes to external shocks, which is critical for a company with a volatile reputation and a dependence on clinical trial results amid frequent secondary offerings.